[1] 付艳,邢卉春. 原发性肝癌的流行状况及危险因素分析. 中国肝脏病杂志,2014, 6:87-90.
[2] Perz JF,Armstrong GL,Farrington LA,et al.The contributions of Hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.J Hepatol,2006,45:529-538.
[3] 项文清,刘伟. HBx 在原发性肝癌发生中的作用研究进展. 浙江大学学报 (医学版),2010, 39: 333-338.
[4] Murakami Y,Saigo K,Takashima H,et al.Large scaled Analysis of hepatitis B virus(HBV)DNA integration in HBV related hepatocellular carcinomas.Gut,2005,54: 1162-1168.
[5] Papatheodoridis GV,Lampertico P,Manolakopoulos S,et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy:a systematic review.J Hepatol,2010,53:348-356.
[6] Papatheodoridis GV,Manolakopoulos S,Touloumi G,et al. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(S) starting with lamivudine Monother apy:results of the nationwide HEPNET.Greece cohort study.Gut,2011,60:1109-1116.
[7] 黄月华,王战会,曾国兵,等.广东地区原发性肝癌与乙型肝炎病毒基因型的相关性.中华传染病杂志,2007,25:215-218.
[8] Kobayashi S,Ide T,Sata M.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers.J Hepatol,2001,34:584-586.
[9] 顾而立,王虹,等.核苷酸类似物治疗乙型肝炎肝硬化患者发生肝细胞癌的危险因素分析.中华传染病杂志,2014, 32: 733-744.
[10] Hosaka T,Suzuki F,Kobayashi M,et al.Development of HCC inpatients receiving adefovir dipivoxil for lamivudine—resistant hepatitis B virus mutants.Hepatol Res,2010,40:145-152.
[11] Yeh CT,Chen T,Hsu CW, et al.Emergence of the rtAl8IT／sW 172 mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer,2011,11:398.
[12] Liaw YF,Sung JJ,Chow WC,et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med,2004,351:1521-1531.
[13] Wong GL,Chan HL,Mak CW,et al.Entecavir treatment Reduces hepatic events and deaths in chronic hepatitis B Patients with liver cirrhosis.Hepatology,2013,58:1537-1547.
[14] Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of heoatocellular carcinoma: a global and regional perspective. Oncologist, 2010,15: 5-13.
[15] Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national samPle of US Veterans with HCV. Hepatology, 2014,60: 98-105.
[16] Raimondi S, Bruno S, Mondelli MU, et al. HePatitis C virus genotyPe1b as a risk factor for hePatocellular carcinoma develoPment: a meta analysis.J HePatol, 2009, 50:1142-1154.
[17] Hung CH, Chen CH, Lee CM, et al. Role of viral genotyPes and hePatitis B viral mutants in the risk of hePatocellular carcinoma asso ciated with hePatitis B and C dual infection. Intervirology, 2013,56: 316-324.
[18] Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hePatocellular carcinoma. Nat Rev Cancer, 2013, 13: 123-135.
[19] Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol, 2006,7:149 -156.
[20] Chuang SC, La Vecchia C, Boffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett, 2009, 286: 9-14.
[21] 白艺珍,丁小霞.应用暴露限制法评估中国花生黄曲霉毒素风险.中国油粮作物学报,2013,35:211-212.
[22] 武栋梁.浅析生活中的黄曲霉及黄曲霉毒素.生物学教学,2012,37:63.
[23] Wareen JR,Marshall B.Unidentified curved bacilli on gastriceoithelium in active chronic gastritis.Lancet, 1983,1:1273-1275.
[24] International Agency for Research on Cancers. Monographs on the evcluation of carcinogenic risks to humans.Geneva:World Health Organization,1994: 61.
[25] Shah SH, Patel JK, Patel NV, et al. 胃内滞留漂浮给药系统中使用草药根除幽门螺旋杆菌的研究进展.中西医结合学报,2009, 7:976-982.
[26] Huang B, Zhao J,Shen S,et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling.Cancer Res,2007,67:4346-4352.
[27] Maeda S, Akanuma M, Mitsuno Y, et al. Distinct mechanism of Helicobacter pylori-mediated NF-κB activation between gastric cancer cells and monocytic cells.J Biolo Chem,2001,276:44856-44864.
[28] Chiba T, Marusawa H. A novel mechanism for inflammation-associated carcinogenesis;important role of activation-induced cytidine deaminase (AID) in mutation induction.J Mol Med,2009:1023-1027.
[29] 徐美华, 瞿秋, 张桂英.初探幽门螺杆菌与肝硬化及肝硬化并肝癌的关系.中南大学学报 (医学版),2007,32:917-920.
[30] 李东复, 卢琳, 杨贵贞. 幽门螺杆菌感染在肝硬化、 肝癌高动力循环及胃黏膜病变中的作用.中国免疫学杂志,2005,21: 877-879.
[31] Wu XZ, Chen D. Helicobacter pylori and hepatocellular carcinoma: correlated or uncorrelated. Gastroenterol Heptal,2006,21:345-347.
[32] 李文广,诸亚君,张启南,等.高危人群补硒预防肝癌的作用. 广东微量元素与科学,1999,6:23-25.
[33] 孙丽萍. Mg、Cu、Fe、Zn、Se对乙型肝炎病毒的影响.中国公共卫生,2004,20:1381.
[34] 李玲.肝癌患者血清中微量元素的测定研究.实用癌症杂志,2006,21:203-204.
[35] 秋安,仇小强,蒋俊俊,等. 糖尿病与原发性肝癌关系队列研究的 Meta分析. 肿瘤防治研究,2010, 37:97-100.
[36] 陆东东.原发性肝癌发生机制分子生物学研究进展. 肿瘤防治研究, 1994,21: 262-264.
[37] Czyzyk A, Szczepanik Z. Diabetes mellitus and cancer. EurJ Intern Med, 2000, 11: 245-252.
[38] 肖开银, 黎乐群, 彭民浩,等. 家族聚集性肝癌101例家族史和临床分析.广西医科大学学报, 2005,22:224.
[39] 施纯朝,薛峰,孙延富,等. 乙型肝炎肝硬化并发原发性肝癌的危险因素. 实用癌症杂志,2013,28: 399-401.
[40] 孙立红. 原发性肝癌饮食危险因素的流行病学研究. 中国卫生统计, 2010, 27: 269-277.
[41] Qiu DC,Hubbard AE, Zhong B,et al. A matched case-control study of the association between Schistosomajaponicum and liver and colon cancer,in rural China.Ann Trop Med Parasitol,2005,99:47-52.
[42] 孙战国. 乙型肝炎患者肝癌患病因素风险及其预防分析.医学理论与实践,2015, 28: 203-204.
[43] Gurtsevitch VE. Human oncogenic viruses: hePatitis B and hepatitis C viruses and their role in hePatocarcinogenesis. Biochemistry(Mosc),2008, 73:504-513.
[44] Malek NP, Schmidt S, Huber P, et al. The diagnosis and treatment of hePatocellular carcinoma.Dtsch Arztebl Int, 2014,111: 101-106.
[45] Chen JG ,Zhang SW. Liver cancer epidemic in China: past, present and future.Semin Cancer Biol, 2011,21:59-69.
[46] 裴丽玲,李建生,任维华. miRNAs与肝细胞癌发生研究进展.实用肝脏病杂志,2014,17: 221-224. |
